The global central lab market is poised for significant growth, with its valuation projected to increase from USD 2,543.9 million in 2023 to USD 4,473.5 million by 2033. This expansion reflects a healthy compound annual growth rate (CAGR) of 5.8% over the forecast period. As the demand for advanced clinical trial support services grows, central labs are playing a pivotal role in accelerating drug development and improving the efficiency of research processes.
Key factors driving the market’s expansion include the surge in clinical trials and the rising prevalence of genetic illnesses, which require sophisticated testing and analysis. Central labs are instrumental in expediting research timelines, ensuring the rapid and accurate delivery of results for pharmaceutical, biotechnology, and medical device companies. This trend is further supported by the need to reduce the high costs associated with drug development and streamline R&D processes.
The role of central labs in the global healthcare ecosystem is becoming increasingly vital. By offering comprehensive drug development solutions, these facilities enable the rapid development of new medications and medical devices. With technological advancements, central labs have improved the speed, accuracy, and reliability of trial results, making them indispensable partners for pharmaceutical and biotechnology companies.
Get Full Report Now – https://www.futuremarketinsights.com/reports/central-lab-market
Key Takeaways:
- The global central lab market is expected to grow from USD 2.54 billion in 2023 to USD 4.47 billion by 2033, with a CAGR of 5.8%.
- The market’s growth is driven by increased clinical trials, a rising prevalence of genetic illnesses, and the need for faster and more accurate testing solutions.
- Central labs play a crucial role in supporting the pharmaceutical, biotechnology, and medical device sectors by providing drug development solutions and services.
- The growing focus on cost reduction in pharmaceutical R&D is propelling the demand for efficient and cost-effective central lab services.
With the rapid pace of drug development and the emergence of new medical devices, the role of central labs is set to expand. Their contributions are vital to optimizing clinical trial outcomes and enabling faster, more cost-effective development of life-saving drugs and therapies.
Key Trends Driving Market Growth
- Increase in Clinical Trials: The rise in clinical trials, particularly those focused on genetic illnesses, is propelling demand for central lab services.
- Rapid Development of New Medications: Continuous innovation in medications and medical devices through clinical trials at central labs enhances treatment options.
- Faster and More Accurate Results: Central labs ensure quicker and more precise test results, which are crucial for timely patient care.
- Cost Efficiency in Drug Development: There is a pressing need to reduce the costs associated with pharmaceutical research and development, making central labs an attractive solution for many companies.
Market Dynamics
The central lab market is bolstered by increasing investments from pharmaceutical and biotechnology companies. These organizations are keen to outsource laboratory services to minimize research costs and improve efficiency. The COVID-19 pandemic highlighted the importance of central labs, particularly for genetic sequencing and rapid testing, further solidifying their role in the healthcare ecosystem.
Central Lab Market Competitive Landscape
Multinational corporations are noticeably at the forefront of the adoption of services provided by central labs because of the many advantages they provide. Furthermore, to enhance the services provided by the central lab business, global market players are adopting collaborations and agreements as essential development tactics.
Emmes is a renowned organization that provides full-service clinical research with a focus on rare diseases. Likewise, the ICON plc acquired MolecularMD laboratory in February 2019. It is a molecular diagnostic specialty laboratory that facilitates discovering, developing, and commercializing discovered medicines for cancer treatment. It aims to expand ICON’s testing platforms, including next-generation sequencing and immunohistochemistry, by improving the laboratory’s ability in molecular diagnostic testing.
Regional expansion to Asian countries is a strategy for global businesses to expand after the saturation of current distribution channels. Many central lab service providers in the United States are employing this strategy to draw in additional clients from adjacent countries and Latin America.
The Alba Campus in Livingston, Scotland, expanded its laboratory and operational capabilities starting in June 2021, according to a statement from Q2 Solutions. Alba Camus is a premier global provider of clinical trial services for pharmaceutical laboratories and supports new growth areas for biopharma and pharma clients globally. Besides being a wholly owned subsidiary of IQVIA, it is expanding its capabilities for genomics, flow cytometry, and translational science laboratory services.
Recent Development
- The CRO announced in September 2021 that it has extended its partnership with Eurofins Central Laboratory by signing a five-year service agreement.
- In 2023, Ampath expanded its reference lab in India, Gurgaon. The lab offers diagnostic tests in hematology, clinical pathology, serology, immunology, and microbiology.
- In 2023, Karkinos Healthcare collaborated with Bayer, a pharmaceutical company in India, to strengthen its oral, breast, cervix, colorectal, and prostate cancer screening.
Key Players Profiled in the Central Lab Market Report
- Covance (Labcorp)
- Eurofins Global Central Library
- PPD Central Lab
- ICON Central Labs
- Medpace Reference Laboratory
- Q² Solutions
- ACM Global Laboratories
- Labconnect Inc.
- Cerba Research
- Medicover Integrated Clinical Services
- Versiti Inc.
- A.P. Moller Holding A/S
- Ampersand Capital Partners
- Lambda Therapeutics Research Ltd
- Cirion Biopharma Research Inc.
Key Segments Profiled in the Central Lab Industry Survey
By Service Type:
- Genetic Services
- Biomarker Services
- Microbiology Services
- Special Chemistry Services
- Other Service Types
By End User:
- Pharmaceutical Companies
- Biotechnology Companies
- Academic and Research Institutes
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan
- Japan
- The Middle East & Africa (MEA)
Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:
Pneumococcal Vaccines Industry
MRI Guided Neurosurgical Ablation Indusrty
Vision Care Industry
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube